Guggenheim cuts Compass Therapeutics stock price target on FDA trial requirement - Investing.com UK

Source: Investing.com UK · 2026-09-23T11:38:00+00:00

Guggenheim cuts Compass Therapeutics stock price target on FDA trial requirement Investing.com UK

BestAIBroker analysis

Finance-aware sentiment: negative (-0.40 on a -1 to +1 scale).
Event classification: OTHER.
Market importance score: 31/100, weighting entity relevance, source credibility, multi-outlet coverage and recency.
Symbols referenced: CMPX, UK.